TUKYSA® (tucatinib) Reimbursed in Ontario, Manitoba and Saskatchewan for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer
Ontario, Manitoba and Saskatchewan join Alberta, British Columbia and Quebec in Adding TUKYSA to their Provincial Formularies TUKYSA is the First HER-2 Directed Therapy to Significantly Extend Overall Survival in Patients with Metastatic HER2-positive Breast Cancer, who Received… Read More




